Tumour oncogenes include transcription factors that co-opt the general transcriptional machinery to sustain the oncogenic state 1 , but direct pharmacological inhibition of transcription factors has so far proven difficult 2 . However, the transcriptional machinery contains various enzymatic cofactors that can be targeted for the development of new therapeutic candidates 3 , including cyclin-dependent kinases (CDKs) 4 .
Here we present the discovery and characterization of a covalent CDK7 inhibitor, THZ1, which has the unprecedented ability to target a remote cysteine residue located outside of the canonical kinase domain, providing an unanticipated means of achieving selectivity for CDK7. Cancer cell-line profiling indicates that a subset of cancer cell lines, including human T-cell acute lymphoblastic leukaemia (T-ALL), have exceptional sensitivity to THZ1. Genome-wide analysis in Jurkat T-ALL cells shows that THZ1 disproportionally affects transcription of RUNX1 and suggests that sensitivity to THZ1 may be due to vulnerability conferred by the RUNX1 super-enhancer and the key role of RUNX1 in the core transcriptional regulatory circuitry of these tumour cells. Pharmacological modulation of CDK7 kinase activity may thus provide an approach to identify and treat tumour types that are dependent on transcription for maintenance of the oncogenic state.
In an effort to discover new inhibitors of kinases that regulate gene transcription, we performed cell-based screening and kinase selectivity profiling of a library of known and novel ATP-site-directed kinase inhibitors (see Supplementary Table 1 for known CDK7 inhibitors). We identified THZ1 (Fig. 1a) , a phenylaminopyrimidine bearing a potentially cysteine-reactive acrylamide moiety, as a low nanomolar inhibitor of cell proliferation and biochemical CDK7 activity (Fig. 1b, c) . To investigate the functional relevance of the acrylamide moiety, we prepared a noncysteine reactiveanalogue,THZ1-R,whichshowedcomparativelyless activity on CDK7 and reduced antiproliferative potency (Fig. 1b, c) . KiNativ profiling 5 , which measures the ability of a compound to block nucleotidedependent enzymes from biotinylation with a reactive desthiobiotin-ATP probe, established CDK7 as the primary intracellular target of THZ1, but not of THZ1-R (Supplementary Table 2 ). Kinome-wide profiling identified additional kinase targets of THZ1; however, we confirmed CDK7 as the only target showing time-dependent inhibition, which is suggestive of covalent binding (Extended Data Fig. 1a -c and Supplementary Table 3 ).
As no covalent inhibitors of CDKs have been reported, we next focused our studies on the mechanism by which THZ1 could achieve covalent inhibition of CDK7. We first incubated a recombinant CDK7-cyclin H-MAT1 (MAT1 also known as MNAT1) trimeric complex with a biotinylated version of THZ1 (bio-THZ1; Fig. 1a ) and demonstrated that it indeed covalently modifies CDK7 ( Fig. 2a and Extended Data Fig. 1d -g). Mass spectrometry identified the site of covalent modification as C312, a residue located outside the kinase domain (Extended Data Fig. 2a-d ). Inspection of the crystal structure revealed that a carboxy-terminal extension of CDK7 bearing C312 traverses the ATP cleft in the kinase domain and would be predicted to position C312 directly adjacent to the reactive acrylamide moiety of THZ1 ( Fig. 2b ). Mutation to serine (C312S), a less nucleophilic amino acid, prevented THZ1 from covalently binding to CDK7 and from inhibiting CDK7 activity in an irreversible fashion ( Fig. 2c and Extended Data Fig. 2e ). Sequence alignment of the 20-member CDK family suggests that C312 is unique to CDK7; however CDK12 and CDK13 also possess accessible cysteines within four amino acids of C312 (Extended Data Fig. 3a ). Indeed, we found that THZ1 can inhibit CDK12 kinase activity at slightly higher concentrations (Extended Data Fig. 3b -f). To our knowledge, THZ1 is the first inhibitor that has been demonstrated to target a cysteine located outside of the kinase domain, which provides an unanticipated means of achieving covalent selectivity.
CDK7 kinase activity has been implicated in the regulation of both transcription, where it phosphorylates the C-terminal domain (CTD) of RNAP polymerase II (RNAPII) [6] [7] [8] Fig. 4a-e ). We observed a loss of CAK activity, as evidenced by decreased phosphorylation of the activation loops of CDK1, 2 and 9, indicating disruption of both recognized CDK7 signalling pathways in Jurkat cells ( Fig. 2d and Extended Data Fig. 4f , g) and Loucy cell lines (Extended Data Fig. 4 ). Ectopic expression of doxycycline-inducible Flag-tagged CDK7 C312S, but not Flag-CDK7 wild type, in HeLa S3 cells restored RNAPII CTD phosphorylated (p)-Ser 5/7 to near wild-type levels at concentrations of THZ1 up to 2.5 mM, establishing C312 as a critical determinant of the cellular pharmacology of the inhibitor (Extended Data Fig. 5a, b ). Additionally, Flag-CDK7 C312S expression restored CDK1/2 T-loop phosphorylation, reduced early induction of cleaved poly-ADP ribose polymerase (PARP) and restored the expression of a subset of genes, including the highly expressed transcription factors MYC, KLF4, ID1 and GATA2 (Extended Data Fig. 5c-e ). The partial rescues of the hyperphosphorylated form of RNAPII (RNAPII0) and RNAPII p-Ser 2 CTD phosphorylation combined with the incomplete restoration of gene expression may result, in part, from lower-affinity cross-reactivity of THZ1 with CDK12 and 13, which are bona fide Ser 2 kinases 15 .
Our evidence that CDK7 inhibition leads to a reduction in RNAPII CTD phosphorylation status seems to be in conflict with evidence that inhibition of CDK7 alone is insufficient to reduce RNAPII CTD phosphorylation in HCT116 cells 9 . It is possible that covalent inhibition and reversible inhibition can engender different effects on kinase structure; we did not find evidence that THZ1 affects TFIIH or CAK complex stability (Extended Data Fig. 4h ). It is also possible that inhibition of CDK12/13 (or CTD phosphorylation by covalently targeting a unique cysteine located outside the kinase domain of CDK7. a, Bio-THZ1 binds irreversibly to CDK7. Recombinant CAK complex was incubated with bio-THZ1 with or without THZ1 at 37 uC for 4 h and biotinylated proteins were resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). IB, immunoblot. b, Docking model of THZ1 in the ATP-binding pocket of CDK7 (Protein Data Bank accession 1UA2). CDK7 is depicted with grey ribbons and THZ1 in turquoise. Key residues are indicated. C312 has been modelled into the crystal structure. c, Mutation of C312 to serine (C312S) rescues wildtype kinase activity in the presence of THZ1. HCT116 cells stably expressing Flag-tagged CDK7 proteins were treated with THZ1 or THZ1-R for 4 h. Exogenous CDK7 proteins were immunoprecipitated with Flag antibody and subjected to in vitro kinase assays. CS, Coomassie stain; KD, kinase-dead; WT, wild type. d, THZ1 inhibits RNAPII CTD phosphorylation. Jurkat cells were treated with THZ1 or THZ1-R for 4 h and proteins of interest were resolved by SDS-PAGE. e, THZ1, but not THZ1-R, shows irreversible inactivation of CDK7. Jurkat cells were treated with THZ1 or THZ1-R for 4 h followed by washout of inhibitor-containing medium. Cells were then allowed to grow in medium without inhibitor for 0-6 h. 'N' indicates no washout, meaning that cells were treated with compound for the duration of the experiment (10 h). f, Antiproliferative effects of THZ1 are impervious to inhibitor washout. Jurkat cells were treated with THZ1 or THZ1-R in dose-response format for 72 h. Experiments were performed in biological triplicates. Error bars show 6 s.d.
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another undetected kinase) contributes to reduced RNAPII CTD phosphorylation, although our evidence that RNAPII CTD phosphorylation levels are restored after expression of CDK7 C312S suggests otherwise.
To understand better the breadth of antiproliferative activity of THZ1, we screened it against a diverse panel of over 1,000 cancer cell lines 16 . THZ1 showed broad-based activity with half-maximum inhibitory concentration (IC 50 ) values less than 200 nM against 53% of the cell lines tested ( Fig. 3a and Supplementary Table 4 ). Elastic net regression analysis incorporating gene expression, copy number and sequence variation genomics data 16 across 527 of the cell lines tested were used to identify genomic features common to sensitive cell lines. Gene ontology (GO) term enrichment analysis 17 indicated a strong enrichment of (proto-) oncogenic transcription factors commonly overexpressed in cancer and factors involved in RNAPII-driven transcriptional regulation, suggesting that the dominant activity of THZ1 was through modulation of transcription ( Fig. 3b and Supplementary Table 5 ).
In agreement with the net elastic regression analysis, T-ALL cell lines that show characteristic misregulation of T-cell lineage-specific transcription factors were broadly sensitive to THZ1, but not to THZ1-R ( Fig. 3c , Extended Data Fig. 6a and Supplementary Table 4 ). Treatment of T-ALL cell lines with THZ1 caused decreased cellular proliferation and an increase in apoptotic index with concomitant reduction in antiapoptotic proteins, most notably MCL1 and XIAP (Extended Data Figs 6 and 7). These strong antiproliferative responses induced at sub-effective doses of THZ1 suggest that T-ALL cells may be particularly sensitive to small perturbations in transcription and CDK7 kinase function. Indeed, THZ1 potently reduced the viability of patient-derived T-ALL and chronic lymphocytic leukaemia (CLL) cells (Extended Data Fig. 8a, b ). Moreover, THZ1 exhibited efficacy in a bioluminescent xenografted mouse model using the human T-ALL cell-line KOPTK1, when dosed twice daily at 10 mg kg 21 (Fig. 3d , e, Extended Data Fig. 8 and Supplementary Table 6 ). Importantly, THZ1 was well tolerated at these doses with no observable body weight loss or behavioural changes (Extended Data Fig. 8f ), suggesting that it caused no overt toxicity in the animals. These results were mirrored in cell culture with non-transformed BJ fibroblast and retinal pigment epithelial (RPE-1) cells responding to relatively high doses of THZ1 by undergoing cell-cycle arrest rather than initiating apoptosis or cell death, further suggesting that normal cells might tolerate transcriptional disruption (Extended Data Fig. 9 ).
CDK7 is a component of the general transcription factor IIH (TFIIH) complex [18] [19] [20] , so we next investigated how THZ1 treatment affects genomewide gene expression. We chose Jurkat T-ALL cells for these studies because it is a well-studied T-ALL cell-line model with a defined core transcriptional regulatory circuitry consisting of key transcription factors, which is also found in human T-ALL primagrafts 21 . Treatment with 250 nM THZ1, but not THZ1-R, led to progressive reduction in global steady-state messenger RNA levels over time, with 75% and 96% of mRNAs showing greater than two-fold reduction by 6 and 12 h, respectively (Fig. 4a , Extended Data Fig. 10a and Supplementary Table 7 ). Consistent with global downregulation of mRNA transcripts, 250 nM THZ1 reduced RNAPII occupancy genome wide at both promoters and gene bodies (Fig. 4b ). By comparison, Flavopiridol reduced RNAPII density only across gene bodies (Fig. 4b) . This is consistent with the model that CDK7 regulates RNAPII initiation and pausing whereas CDK9 regulates pause release leading to processive elongation 8, 9, [18] [19] [20] [22] [23] [24] .
Although 250 nM THZ1 inhibits global transcription, we found that some cancer cell lines, particularly T-ALL, are sensitive to considerably lower concentrations of THZ1. We postulated that the expression of certain genes might be especially sensitive to low doses of THZ1 and reduces the proliferation of KOPTK1 T-ALL cells in a human xenograft mouse model. Bioluminescent images of two representative mice treated with either vehicle control, 10 mg kg 21 THZ1 once daily (qD), or 10 mg kg 21 THZ1 twice daily (BID) for 29 days. e, Relative bioluminescence of mice treated with vehicle, 10 mg kg 21 THZ1 once daily, or 10 mg kg 21 THZ1 twice daily during the 29 days of treatment. n 5 10 for all groups. Bioluminescence is shown relative to day 0 and is plotted as average 6 standard error of the mean. Analysis of the bioluminescence data by repeated measures two-way analysis of variance (ANOVA) reveals that the antiproliferative effect of treatment with THZ1 twice daily is highly statistically significantly different (P , 0.0001) as compared with the other treatments.
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therefore have a key role in driving the cellular response. Indeed, we found that transcripts for only a subset of genes were substantially affected by treatment with 50 nM THZ1, with that for RUNX1 among the most profoundly affected (Fig. 4c ). There are at least two reasons that low-dose THZ1 treatment might cause a preferential loss of RUNX1 expression. Tumour-cell oncogenes can acquire super-enhancers, which drive high-level expression yet can be especially sensitive to perturbation [25] [26] [27] [28] . Super-enhancer analysis in Jurkat cells revealed that RUNX1 contains an exceptionally large super-enhancer domain containing a previously described haematopoietic-cell-specific enhancer (Fig. 4d , Extended Data Fig. 10b-d and Supplementary Table 8 ) 29 . In addition, RUNX1 forms a core regulatory circuitry with two additional transcription factors that have prominent roles in leukaemia biology, TAL1 and GATA3 (Fig. 4e) 21 .
These factors autoregulate their own gene expression while simultaneously regulating many other genes that comprise the active gene expression program of Jurkat cells. Treatment with 50 nM THZ1 led to a significant reduction in both the transcript and protein levels of RUNX1, TAL1 and GATA3 (Extended Data Fig. 10e, f) . Loss of the RUNX1-driven transcriptional program is probably key to the response to low-dose THZ1 treatment, as gene set enrichment analysis revealed that the Jurkat transcripts downregulated by 50 nM THZ1 were enriched in transcripts similarly downregulated after RUNX1 depletion using short hairpin (sh)RNA (Fig. 4f) .
We have reported the discovery and characterization of a covalent inhibitor of CDK7, THZ1. THZ1 uses a unique mechanism, combining ATP-site and allosteric covalent binding, as a means of attaining potency and selectivity for CDK7. This mechanistic insight should be useful for designing next-generation inhibitors of CDKs, for which high sequence and shape homology in the ATP pocket has posed a formidable challenge to achieving selectivity with conventional ATP-competitive inhibitors. THZ1 showed potent antiproliferative activity on T-ALL cell lines and other blood cancers, in which oncogenic transcription factors feature prominently in the disease state. In Jurkat cells, low-dose THZ1 had a profound effect on a small subset of genes, including the key regulator RUNX1, thus contributing to subsequent loss of the greater gene expression program and cell death. Identification of additional cancer cell lines whose gene expression programs show vulnerability to THZ1 or other transcriptional inhibitors should delineate other cancers that are susceptible to perturbation of transcription.
METHODS SUMMARY
T-ALL culture conditions. Jurkat, Loucy, KOPTK1 and DND-41 cell lines were grown in RPMI-1640 supplemented with 10% fetal bovine serum (FBS) and 1% glutamine. All cell lines were cultured at 37 uC in a humidified chamber in the presence of 5% CO 2 , unless otherwise noted. 
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Inhibitor treatment experiments. Time-course experiments such as those described in Extended Data Fig. 5a were conducted to determine the minimal time required for full inactivation of CDK7. Cells were treated with THZ1, THZ1-R or dimethylsulphoxide (DMSO) for 0-6 h to assess the effect of time on the THZ1-mediated inhibition of RNAPII CTD phosphorylation. For subsequent experiments cells were treated with compounds for 4 h as determined by the time-course experiment described earlier, unless otherwise noted. For inhibitor washout experiments (Fig. 2e, f and Extended Data Fig. 5 ) cells were treated with THZ1, THZ1-R or DMSO for 4 h. Medium containing inhibitors was subsequently removed to effectively 'washout' the compound and the cells were allowed to grow in the absence of inhibitor. For each experiment, lysates were probed for RNAPII CTD phosphorylation and other specified proteins.
High-throughput cell-line panel viability assay. Cells were seeded in 384-well microplates at ,15% confluency in medium with 5% FBS and penicillin/streptavidin. Cells were treated with THZ1 or DMSO for 72 h and cell viability was determined using resazurin. RNA extraction and synthetic RNA spike-in. Total RNA and sample preparation was performed as previously described 30 . Briefly, after inhibitor treatment cell number was determined, total RNA was isolated, and ERCC RNA Spike-In Mix (Ambion, catalogue no. 4456740) was added to total RNA relative to cell number. Expanded protocols and synthetic chemistry schemes can be found in Supplementary Information.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. (20, 60 and 180 min), demonstrating that THZ1 but not THZ1-R shows time-dependent inhibition of CDK7. b, c, Pre-incubation of THZ1 increases CDK7 inhibitory activity in vitro. Recombinant CAK complex was incubated with THZ1 (b) or THZ1-R (c) in a dose-response format with or without pre-incubation before ATP (25 mM) addition. The kinase reaction was then allowed to proceed for 45 min at 30 uC. d, Workflow of bio-THZ1 pulldown competition experiment. e, Bio-THZ1 pulls down CDK7 from cellular lysates. Loucy cellular lysates were incubated with bio-THZ1 (1 mM) with or without THZ1 (10 mM) and streptavidin-precipitated proteins were probed for CDK7. IB, immunoblot. f, Free intracellular THZ1 competes in a dosedependent manner for bio-THZ1 binding to CDK7. Loucy cells were treated with increasing concentrations of THZ1 or with 10 mM THZ1-R for 4 h. Cellular lysates were incubated with bio-THZ1 and processed as indicated in a. g, Bio-THZ1 labels CDK7 in lysates. Loucy cellular lysates were incubated with bio-THZ1 at 4 uC for 12 h followed by immunoprecipitation of CDK7 at 4 uC for 3 h. Precipitated proteins were washed and probed with horseradish peroxidase (HRP)-conjugated streptavidin.
Extended Data Figure 2 | THZ1 covalently binds CDK7 C312. a, b, Total ion chromatograms (TIC) and extracted ion chromatograms (XIC) for CDK7 peptides recorded during analysis of CAK complexes treated with DMSO (a) or THZ1 (b). c, Efficiency of labelling was estimated to be approximately 85%, as gauged by the reduction in signal of triply and quadruply charged YFSNRPGPTPGCQLPRPNCPVETLK ions (residues 294-318). The peptides VPFLPGDSDLDQLTR (residues 180-194) and LDFLGEGQFATVYK (residues 15-28) were used for normalization. d, Orbitrap HCD tandem mass spectrometry (MS/MS) spectrum of a quadruply charged CDK7-derived peptide (residues 294-318) labelled by THZ1 at C312. Fragment ions containing the peptide C terminus (y-type) or N terminus (b-type), along with the associated mass errors are shown in red and blue, respectively. Fragment ions marked by an asterisk contain the inhibitor and have the expected heavy isotope contribution from chlorine. The site of labelling was determined to be C312 (as opposed to C305) on the basis of fragment ions observed in additional MS/MS spectra (for example, y11 31 observed with ,3 p.p.m. mass error by fragmentation of the 16 charged precursor; see inset mass spectrum). e, C312S mutation eliminates THZ1 covalent binding. Cellular lysates from HCT116 cells expressing either Flag-CDK7 wild type or C312S were incubated with bio-THZ1 for 12 h at 4 uC and then at room temperature for 3 h to facilitate covalent binding. Precipitated proteins were then probed for the presence of Flag-tagged CDK7. and partially rescues Ser 2 RNAPII CTD phosphorylation. a, Expression of C312S rescues Ser 5/7 and partially rescues Ser 2 RNAPII CTD phosphorylation. HeLa S3 cells stably carrying a doxycycline-inducible Flag-CDK7 C312S construct were treated with THZ1 or DMSO for 5 h with or without the presence of doxycycline. Cellular lysates were then probed for the indicated proteins. b, Phenotypic rescue is specific to the C312S mutation, as rescue is not achieved with overexpression of Flag-CDK7 wild type (WT). HeLa S3 cells stably carrying doxycycline-inducible Flag-CDK7 wild-type and C312S constructs (or empty vector) were treated with THZ1 or DMSO for 5 h in the presence of doxycycline. c, Expression of C312S largely restores CDK1/2 T-loop phosphorylation. HeLa S3 cells stably carrying a doxycyclineinducible Flag-CDK7 C312S construct were treated with THZ1 or DMSO for 5 h with or without the presence of doxycycline. Cellular lysates were then probed for the indicated proteins or phosphoproteins. d, Overexpression of Flag-CDK7 C312 rescues the expression of a subset of transcripts in HeLa S3 cells. Log 2 fold change in gene expression in HeLa S3 cells expressing Flag-CDK7 wild type (x-axis) and Flag-CDK7 C312S (y-axis) after a 4 h treatment with 500 nM THZ1. e, GO molecular function analysis of transcripts increased by 1 log 2 order or more after expression of Flag-CDK7 C312S compared with Flag-CDK7 wild type in the presence of 500 nM THZ1.
RESEARCH LETTER

LETTER RESEARCH
Extended Data Figure 8 | THZ1 demonstrates potent killing of primary chronic lymphocytic leukaemia cells and antiproliferative activity against primary T-ALL cells and in vivo against a human T-ALL xenograft. a, Patient-derived chronic lymphocytic leukaemia (CLL) samples were obtained and cultured in vitro for 24 hours in the presence of escalating doses of the specified compounds (n 5 10 samples, 1 technical replicate per condition, per sample). Cell death upon compound exposure was evaluated using FITC Annexin V Apoptosis Kit I (BD Biosciences) and 1x10 4 events were collected and analysed using a BD FACSCanto II flow cytometer. Results shown are mean normalized percentage death based on Annexin V and propidium iodide single-and double-positive cells (6 s.d.) normalized to baseline death in the vehicle (DMSO) control condition of each sample. Compounds tested were THZ1, THZ1-R and Flavopiridol (THZ1 versus THZ1-R P 5 1.5 3 10 238 ; THZ1 versus Flavopiridol P 5 0.05). P values were generated using an ANOVA model. b, Patient-derived xenografts (patient IDs 3255-1, M18-1-5 and D135-1-5; n 5 3) were treated with THZ1 for 3 h followed by compound washout. An aliquot of input cells was then counted by flow cytometry using a known quantity of flow cytometry calibration beads (data not shown; Molecular Probes). The remaining cells were plated onto MS5-DL1 feeder cells in the presence of serum-free media (supplemented with 0.75 mM SR1, 10 ng ml 21 interleukin (IL)-7, 10 ng ml 21 IL-2). Seventy-two hours later, cultures were harvested by vigorous pipetting with Trypsin, filtered through nylon mesh to deplete feeders, and counted by flow cytometry using a known quantity of flow cytometry calibration beads and with gating to discriminate between T-ALL cells and carryover feeders. The final cell number was normalized to the input cell number to calculate fold expansion. This experiment was performed once per patient-derived sample. c, Bioluminescent images of two representative mice treated with either vehicle control, 10 mg kg 21 THZ1 once daily (qD), or 10 mg kg 21 THZ1 twice daily (BID) for the indicated number of days. d, Spleen tissue from mice treated with THZ1 shows decreased RNAPII CTD phosphorylation. Mice were treated with THZ1 10 mg kg 21 once daily or twice daily or vehicle control. The animals were killed and spleen tissues were isolated. Lysates prepared from homogenized spleen tissue were probed for RNAPII CTD phosphoepitopes. e, THZ1 binds directly to CDK7 in mouse tissues. Mice were treated with THZ1 10 mg kg 21 once daily or twice daily or vehicle control. The animals were killed and spleen tissues were isolated. Lysates prepared from homogenized spleen tissue were incubated with bio-THZ1 for 12 h at 4 uC and 2 h at room temperature to induce covalent bond formation. Proteins pulled down were then probed for the presence of CDK7. f, Body weights of mice treated with either vehicle control, 10 mg kg 21 THZ1 once daily, or 10 mg kg 21 THZ1 twice daily over the duration of the drug treatment.
